Welcome to our dedicated page for Pulse Biosciences SEC filings (Ticker: PLSE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pulse Biosciences, Inc. (Nasdaq: PLSE) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered summaries to help interpret complex documents. As a medical device developer focused on bioelectric medicine and nanosecond pulsed field ablation (nsPFA) technology, Pulse Biosciences uses its SEC filings to describe clinical programs, financial performance, governance matters and key milestones for its nPulse platforms.
Investors can review Form 10-K and 10-Q filings for detailed discussions of the company’s business, risk factors, research and development spending and revenue from nPulse capital equipment and Vybrance disposables. Form 8-K current reports highlight material events such as FDA Investigational Device Exemption (IDE) approvals for the NANOCLAMP AF and NANOPULSE-AF atrial fibrillation studies, publication of first-in-human thyroid data, initiation of clinical trials, and quarterly business updates and financial results.
The company’s DEF 14A definitive proxy statement outlines corporate governance, board structure, equity incentive plans and executive compensation policies, providing insight into how management and directors are incentivized as Pulse Biosciences advances its nsPFA technology. Other exhibits and schedules within these filings can include information on stockholder votes, amendments to equity plans and non-GAAP financial measures used by management.
On Stock Titan, each PLSE filing is supplemented with AI-generated explanations that clarify technical language, summarize key sections and point out items such as clinical trial descriptions, regulatory designations and capital structure changes. Users can also monitor Form 4 insider transaction filings when available to see how officers and directors transact in company stock. Together, these tools allow investors, analysts and clinicians to quickly understand the implications of Pulse Biosciences’ SEC filings without reading every line of each document.
Pulse Biosciences (PLSE) reported Q3 2025 results. Product revenue was $86 thousand. Operating expenses totaled $20.5 million, driven by research and development of $11.4 million and selling, general and administrative of $8.8 million. The company recorded a net loss of $19.4 million (basic and diluted net loss per share of $0.29).
Cash and cash equivalents were $95.2 million as of September 30, 2025, compared with $118.0 million at year‑end 2024. Net cash used in operating activities was $39.4 million for the nine months ended September 30, 2025. Financing inflows included $14.1 million from warrant exercises, $2.1 million from option exercises, and $0.6 million from the employee stock purchase plan.
The company began capitalizing inventory for the Vybrance Percutaneous Electrode System after FDA 510(k) clearance and commenced the PRECISE BTN clinical trial in September 2025 to support U.S. commercialization, targeting up to 50 patients across up to four sites, with over twenty patients treated to date. Common shares outstanding were 67,738 thousand as of September 30, 2025, and 67,767,578 as of October 31, 2025.
Pulse Biosciences (PLSE) furnished an 8-K announcing it issued a press release with financial and operational results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference. The company states this information is being furnished and shall not be deemed filed under the Exchange Act.
The filing reiterates the company’s common stock trades on Nasdaq under the symbol PLSE. The press release, dated November 5, 2025, provides the detailed business update and quarterly results referenced in this report.
Pulse Biosciences (PLSE) filed its definitive proxy for a virtual annual meeting on December 9, 2025 at 11:00 a.m. ET. Stockholders will vote to elect six directors, ratify Deloitte & Touche LLP as auditor for 2025, approve a non-binding “say-on-pay,” and select the frequency of future say‑on‑pay votes.
The record date is October 22, 2025. 67,757,578 shares were outstanding and entitled to vote as of that date; a majority present constitutes a quorum. The board recommends voting for all director nominees, for auditor ratification, for executive compensation, and for say‑on‑pay frequency of every three years.
The company discloses that since January 9, 2025 its Audit Committee has had two independent members, below Nasdaq’s three‑member requirement; the board is evaluating candidates and intends to appoint a third member within the permitted cure period. Robert W. Duggan beneficially owns 72.1% of common stock as of October 22, 2025. Auditor fees billed by Deloitte for 2024 totaled
Pulse Biosciences (PLSE) announced first patient enrollment in its NANOCLAMP AF clinical trial, a single-arm, prospective multicenter study evaluating the safety and effectiveness of the nPulse Cardiac Surgical System for treating atrial fibrillation during concomitant surgical procedures.
The company reported that the first procedure was successfully completed at St. Helena Hospital in St. Helena, California. A related press release was furnished as Exhibit 99.1. This update reflects early clinical progress for the cardiac surgical application of the company’s pulsed-field technology.
Pulse Biosciences reported late-breaking first‑in‑human feasibility results for its nPulse™ Cardiac Surgical System. The study has treated 44 patients across three investigators, with an initial cohort of 24 patients evaluated by electroanatomical mapping about
Pulse Biosciences insider transactions on
PULSE BIOSCIENCES reported director compensation and a leadership update. The company's board ratified awards granted August 9, 2024, comprising three grants of 200,000 option shares each for a total of 600,000 options. The filing notes 2,753,901 broker non-votes on an item reported as "Against" and includes an entry of "N/A" for related fields. It also states that Mr. LaViolette became President and Chief Executive Officer on January 9, 2025 and remains an ex officio member of the Strategic Advisory Committee.
Pulse Biosciences (PLSE) insider transactions by Kevin Patrick Danahy. The reporting person, the company's Chief Commercial Officer, executed sales and option-related transactions on September 18–19, 2025 under a Rule 10b5-1 trading plan adopted May 14, 2025. On 9/18/2025 he acquired 20,000 shares at $1.53 via option exercise and sold 20,000 shares at a weighted average price of $18.49, leaving 43,298 shares beneficially owned. On 9/19/2025 he exercised 400 shares at $1.53 and sold 400 shares at $18.48; post-transactions his direct beneficial ownership of common stock reported in Table I was 43,298 shares. Options granted 9/23/2022 covering 450,000 shares vest 25% annually; 20,400 options were exercised in these transactions.
Darrin Uecker, Pulse Biosciences (PLSE) Chief Technology Officer and director, reported multiple scheduled trades under a Rule 10b5-1 plan on September 16-17, 2025. He sold 25,000 shares on 9/16 and 20,000 shares on 9/17 at weighted average prices of $16.28 and $16.21 respectively, and purchased shares the same days at an exercise price of $4 under stock options and via market purchases. After the reported transactions his beneficial ownership of common stock is stated as 284,406 shares. Several $4 stock options with various exercisable dates are listed, and the Form notes the trades were executed pursuant to a 10b5-1 plan adopted June 12, 2025.
Form 144 filed for Pulse Biosciences, Inc. (PLSE) reports a proposed sale of 25,000 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $406,750.00. The filing states the shares were acquired and paid for on 09/18/2025 by exercise of stock options from the issuer, and the approximate date of sale is also listed as 09/18/2025.
The filing lists 67,278,347 shares outstanding, and no other sales by the reporting person in the past three months were reported. The filer represents there is no undisclosed material adverse information and includes the standard signed certification language on trading plans and criminal penalties for false statements.